Next Article in Journal
Genotypic Resistance Analysis of Bacterial Species Involved in Infectious Keratitis
Previous Article in Journal
BacT-Seq, a Nanopore-Based Whole-Genome Sequencing Workflow Prototype for Rapid and Accurate Pathogen Identification and Resistance Prediction from Positive Blood Cultures: A Feasibility Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Polymicrobial PID Presenting as Primary Peritonitis in a Young Immunocompetent Patient—Case Report and Disease Perspectives

by
Georgiana Nemeti
1,
Maria Adriana Neag
2,
Iulian Gabriel Goidescu
1,*,
Mihai Surcel
1,
Cerasela Mihaela Goidescu
3,
Ioana Cristina Rotar
1 and
Daniel Muresan
1
1
Obstetrics and Gynaecology I, Mother and Child Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
2
Department of Pharmacology, Toxicology and Clinical Pharmacology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania
3
Department of Internal Medicine, Medical Clinic I—Internal Medicine, Cardiology and Gastroenterology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
Diagnostics 2026, 16(1), 134; https://doi.org/10.3390/diagnostics16010134 (registering DOI)
Submission received: 23 November 2025 / Revised: 17 December 2025 / Accepted: 30 December 2025 / Published: 1 January 2026
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Gynecological Infections)

Abstract

Background and Clinical Significance: Pelvic inflammatory disease represents a multifaceted sexually transmitted disease affecting women of reproductive age, beginning in adolescence. Clinical presentation ranges from asymptomatic patients to acute abdominal pain in the setting of tubo-ovarian abscesses; however, presentation as primary peritonitis with seemingly intact fallopian tubes is exceptional. Primary peritonitis in the absence of other comorbid conditions (e.g., liver cirrhosis and nephrotic syndrome) in healthy, immunocompetent women is rare and typically occurs without an identifiable intra-abdominal source. The diagnosis can be challenging due to its mild-to-moderate, nonspecific symptoms. Case Presentation: We report the case of a 21-year-old immunocompetent woman who presented with lower abdominal and left iliac fossa pain with hyperleukocytosis. Laparoscopic exploration confirmed the diagnosis of primary peritonitis. Following diagnosis, she underwent peritoneal lavage and was started on empiric broad-spectrum parenteral antibiotic therapy. Cervico-vaginal cultures established the diagnosis of PID following identification of Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma parvum. The clinical course was favorable. Conclusions: An early multidisciplinary approach, including consultation with an infectious disease specialist and clinical pharmacologist, is recommended in cases of peritonitis with an unclear source. PID may present as primary peritonitis and this clinical scenario should be considered in sexually active young women with unexplained peritoneal infection when no gastrointestinal or gynecologic source is evident intraoperatively.

1. Introduction

Pelvic inflammatory disease (PID) is a polymicrobial infection that predominantly affects sexually active young cisgender women, but also women of older reproductive age [1]. Upper genital tract inflammatory processes lead to a broad spectrum of conditions, such as acute salpingitis, perihepatitis, endometritis, oophoritis, tubo-ovarian abscess, and pelvic peritonitis [2,3], most commonly caused by the presence of Chlamydia trachomatis and/or Neisseria gonorrhoeae [4]. Frequently, the infection becomes polymicrobial, potentiated by the presence of various vaginal–cervical microorganisms [5,6].
Patients may be asymptomatic, with incidental retrospective diagnosis in suggestive clinical contexts such as surgery for complicated tubal pregnancy, infertility workup, or during pelvic surgery for other indications. Symptoms range from lower abdominal pain, pelvic organ tenderness, and purulent vaginal discharge, and may have an insidious or abrupt onset.
The population most susceptible to PID are adolescents and young females given their topical cervico-vaginal particularities—cervical ectropion and an immature immune system (both local and systemic)—as well as frequently reckless sexual behavior (multiple coital partners, use of non-barrier contraception, ineffective condom usage). Additional risk factors include reproductive age patients with bacterial vaginosis, vaginal douching, coitus during menstruation, and a history of PID episodes (which often lack proper diagnosis and management) [7].
Careful evaluation of PID, especially in the setting of acute presentations, is mandatory to achieve a correct diagnosis and ensure proper and timely management to prevent the development of sequalae.
Primary peritonitis refers to peritoneal inflammation and infection in the absence of any identifiable lesions in the gastrointestinal or genitourinary tracts, or in solid organs [8]. Although its pathogenesis is not fully understood, several mechanisms have been proposed, including bacterial translocation from the intestine, hematogenous dissemination, and retrograde spread from the genitourinary tract [9].
Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma parvum are part of the genital microbiota and fall under the category of sexually transmitted infections (STIs). These organisms typically infect epithelial cells and rarely enter the bloodstream [10,11]. Chlamydia trachomatis is the most prevalent bacterial agent involved in STIs and should always be considered in cases of pelvic inflammatory disease [12]. Mycoplasma hominis also plays a significant role in female reproductive tract inflammation, often in co-infection with Chlamydia, Trichomonas vaginalis, or Neisseria gonorrhoeae, presenting with similar clinical features [10,11,12,13]. Ureaplasma parvum is generally associated with asymptomatic infections, but chronic colonization may contribute to upper genital tract inflammation and, in rare cases, peritonitis [14,15].
In this case report, we present an unusual case of PID manifesting as primary peritonitis with abrupt onset and rapid worsening in a healthy, sexually active young woman, with a polymicrobial sexually transmitted infection panel positive for Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma parvum. Although polymicrobial PID is common, initial presentation as an acute surgical abdomen with primary peritonitis in the absence of macro-lesional tubal damage is exceptional, and even more so in an immunocompetent young patient. This raises awareness regarding the importance of considering such etiologies in the differential diagnosis of acute abdomen, particularly in sexually active patients without identifiable intra-abdominal pathology.

2. Case Presentation

A 21-year-old healthy woman, without relevant obstetrical–gynecologic, medical, or surgical history, with regular menstrual cycles, currently in the periovulatory period, was admitted to our department through the emergency room for pain located in the lower abdomen and left iliac fossa. The pain was intense, with a VAS (Visual Analog Scale) score of 7–8, and persisted regardless of the antalgic and anti-inflammatory medication provided.
The patient was afebrile (temperature 36.6 °C), her blood pressure was 130/60 mmHg, with a normal pulse. Clinical examination revealed a soft and flat abdomen, with spontaneous and palpable pain and tenderness in the left iliac fossa and hypogastrium. The bimanual pelvic examination objectified acute cervical motion, uterine, and adnexal tenderness. Transvaginal ultrasonographic examination revealed a minimal amount of free fluid in the pouch of Douglas, consistent with ovulation, but otherwise normal internal genitalia, confirming the periovulatory stage, and no other pathologic findings of the surrounding organs. Based on clinical and imaging findings, an initial diagnosis of uncomplicated PID was established, and the patient was admitted for surveillance and management. A vaginal discharge slide exam and a swab for sexually transmitted infections (STIs) screening were sampled (NAAT—nucleic acid amplification test). Empiric broad-spectrum antibiotic therapy was initiated, consisting of clindamycin, gentamicin, and ceftriaxone, along with antifungal protection, anti-algic, and anti-inflammatory therapy, gastric protection, and fluid balancing solutions. Initial lab workup showed a leukocyte count of 21,000 × 109/L, a C-reactive protein level of 16.67 mg/dL, a fibrinogen value of 681 mg/dL, a ferritin value of 147 ng/mL, and mildly elevated direct and indirect bilirubin, all supporting an inflammatory state with a mild hepatic response.
Approximately 5 h later, the pain intensified, and upon ultrasound reevaluation, an increased quantity of stained free fluid were identified by endovaginal ultrasound examination in the Douglas pouch and ante-uterine space, which we interpreted as peritonitis. Surgical evaluation was requested, and the common diagnostic achieved was acute surgical abdomen. Given the severe abdominal pain intensifying despite the medication provided, as well as the increasing amount of impure peritoneal fluid, following patient consent and perioperative preparations, an exploratory laparoscopy was performed. At initial examination, approximately 200 mL of purulent effusion was observed in the peritoneal cavity (Figure 1), with an unremarkable-looking uterus, ovaries, and fallopian tubes. There were no signs of adhesions, tubal congestion, enlargement, or purulent discharge coming from the salpinges at the time of exploration; both tubes depicted a normal course. Bacteriological samples were obtained, and abundant peritoneal lavage was carried out. The appendix, intestines, and gallbladder were normal, and no perforation of other pelvic/abdominal organs could be identified. In the absence of a clear source, the diagnosis of primary purulent peritonitis was established, and broad-spectrum antibiotic therapy with piperacillin/tazobactam and doxycycline was started.
Bacteriological samples were negative, but PCR/NAAT (polymerase chain reaction/nucleic acid amplification testing) was not available in the emergency setting. However, the sexually transmitted disease panel from vaginal and cervical secretions was positive for Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma parvum (Table 1). The wet prep revealed abundant leukocytes. Further STI testing for hepatitis B and C, HIV (human immunodeficiency virus), and syphilis were negative.
The postoperative course of the patient was uneventful, with same-day mobilization and transit restoration, as well as a rapid decrease in inflammatory response parameters under the treatment regimen (Table 2). Hepato-protective therapy was initiated due to a mild hepatic reaction. The patient was discharged on day 4 with a doxycycline and amoxicillin–clavulanate antibiotic regimen to be carried out until 14 days of treatment would be completed, as well as single-dose azithromycin therapy for the sexual partner. The choice of the outpatient antibiotic regimen was motivated by a step-down approach while maintaining the antimicrobial profile and the need to cover gut flora translocation despite negative cultures. Extensive patient counseling regarding sexual hygiene, PID episodes prophylaxis, reevaluation schedule, as well as potential long-time sequalae was provided. At 21 days post-surgery, the patient presented for follow-up and was asymptomatic, with a normal pelvic ultrasound and a normal blood test panel. The patient then presented for bi-annual follow-ups, which were unremarkable.

3. Discussion

Pelvic inflammatory disease represents the consequence of ascending pathogen dissemination from the lower to the upper genital tract and the peritoneal cavity, sometimes affecting neighboring pelvic organs (bowel, omentum, bladder).
The hallmark of the disease is pelvic pain and tenderness. In the initial stages of the disease, when tubal compromise is subtle and there are no imaging signs of damage, PID is a diagnosis of exclusion in the context of lower abdominal pain and tenderness, absence of other identifiable genital tract, pelvic, or abdominal organ pathology, and confirmation by positive testing for specific sexually transmitted bacteria.
The most commonly identified agents involved in PID are Chlamydia trachomatis, isolated in 10–43% of cases, and Neisseria gonorrhoeae, found in 25–50% of patients [4,7,16,17]. In 30% of cases, other microorganisms are involved, such as bacterial vaginosis agents, cervical pathogens, enteric bacteria, respiratory microbes, and other anaerobic and facultative species (Table 3). Many cases depict polymicrobial infections; contrarily, in an important share of patients with macro-lesional disease and even purulent vaginal discharge/purulent peritoneal fluid, an etiologic agent is not identified [16].
Factors favoring the occurrence of PID include young age, early age of sexual debut, an immature immune system, an immature cervical tissue represented by columnar epithelium in the transitional zone, which maintains a propitious ambient for the growth of Chlamydia trachomatis and Neisseria gonorrhoeae, multiple sex partners, unhealthy sexual behaviors (inconsistent condom use, contacts during menses, non-barrier contraceptive means), vaginal douching, history of STIs, previous PID episodes, intra-uterine device use (recent insertion, extended use), recent oocyte retrieval or pelvic surgery, and recent endometrial biopsy [18,19]. In many cases of PID, however, no risk factors can be identified. In consistency with literature reports, our patient was young but had no positive history of previous PID episodes, endo-uterine maneuvers, or risky sexual habits.
Patients with PID have varying symptomatology ranging from subtle pain to acute surgical abdomen, often making diagnosis difficult. The presence of sactosalpinx or tubo-ovarian abscesses, with or without pelvic collections, calls for a swift diagnosis. In cases where there is no clear image of adnexal involvement, diagnosis becomes more challenging [20].
Peritonitis is a life-threatening acute surgical emergency requiring prompt intensive care and surgical management and may be classified into three categories: primary (or spontaneous) peritonitis, which occurs in the absence of any intra-abdominal surgical focus; secondary peritonitis, resulting from the loss of integrity of an intra-abdominal organ or a penetrating infectious process; and tertiary peritonitis, defined by the persistence or recurrence of signs and symptoms of peritonitis following adequate treatment of secondary peritonitis [21]. Primary peritonitis is exceptionally rare in young immunocompetent patients, accounting for less than 1% of all peritonitis cases [22].
The case of our patient can be regarded from two equally valid perspectives. On the one hand, as we initially thought, in the context of abdominal pain and pelvic examination tenderness without suggestive imaging findings for intra-abdominal pathology, it can be regarded as uncomplicated PID. As the clinical evolution of the patient swiftly developed towards worsening general status and increasing stained peritoneal fluid collection, in the absence of microbiological confirmation, we then interpreted it as primary peritonitis until cervical test results were available. In reality, rapid development of PID to peritonitis within hours is rare, especially in the absence of long-standing disease and established tubal damage.
The initial treatment regimen chosen was empirical, consistent with the diagnosis of PID, and aimed to cover the most common STI spectrum, associating clindamycin, gentamicin, and ceftriaxone. Timely and correct antibiotic therapy is meant to prevent chronic sequelae such as adhesions, scarring, tubal damage, ectopic pregnancy, infertility, and chronic pelvic pain [20,23]. Following the arrival of culture results confirming the diagnosis of STI, the antimicrobial regimen was adjusted to include piperacillin/tazobactam, a broad-spectrum beta-lactam/beta-lactamase inhibitor combination effective against a wide range of aerobic and anaerobic bacteria. Due to the absence of a peptidoglycan cell wall, Mycoplasma hominis is intrinsically resistant to most broad-spectrum antibiotics, including penicillins, cephalosporins, and carbapenems. Recommended treatment options include tetracyclines or fluoroquinolones [24]. Therefore, doxycycline, a tetracycline-class antibiotic, was added to the therapeutic protocol because it is active against Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma parvum and is considered a first-line agent in the treatment of STIs involving these pathogens. This combined approach ensured both empirical coverage of potential intra-abdominal pathogens and targeted therapy for the identified agents.
To place our case in a broader clinical context, from the perspective of primary peritonitis, Table 4 summarizes previously reported cases and studies involving the main pathogenic agents encountered. It includes key patient characteristics, identified infectious agents, diagnostic methods, and therapeutic approaches. It also highlights the use of empiric broad-spectrum antibiotic regimens, often initiated before pathogen identification and subsequent targeted therapies administered based on microbiological findings.
The exact mechanism through which these genital pathogens reached the peritoneal cavity in our patient remains unclear. However, an ascending infection pathway from the lower genital tract represents the most plausible explanation, especially in the absence of any other identifiable intra-abdominal source, regardless of whether it belongs to the category of STIs. This mechanism has been previously described in cases of pelvic inflammatory disease progressing to pelvic or generalized peritonitis, particularly when infection is left untreated or inadequately treated. However, if this had been the case in our patient, she should either have reported previous episodes of strong abdominal pain, or tubal compromise might have been apparent.
Our patient presented a favorable clinical outcome, even though treatment was empirical due to initially negative culture results. This may be attributed to the fastidious natures of Mycoplasma hominis and Ureaplasma parvum, which require special culture media and conditions not routinely used in standard bacterial cultures. Additionally, prior initiation of antibiotic therapy before surgical sampling could have further reduced the likelihood of isolating viable organisms.
Chienwichai et al. suggest that culture-negative peritonitis is often associated with more favorable clinical outcomes compared to culture-positive cases, despite ongoing uncertainty surrounding its underlying mechanisms [33]. Notably, hypokalemia emerged as a potential predictor of culture-negative peritonitis in that cohort. A plausible mechanism may explain this association—hypokalemi-induced increases in intestinal permeability may facilitate bacterial translocation, particularly of anaerobic and Gram-negative organisms that may evade detection in standard cultures. This factor may contribute to the higher prevalence of hypokalemia observed in culture-negative cases and highlight the need for further investigation into the pathophysiology and diagnostic limitations associated with this condition [33].
Chlamydia trachomatis is the most widespread STI pathogen and most frequently induces a silent but persistent infection leading to inflammation and chronic injury of genital tract tissues [6,7].
Mycoplasma hominis is strongly associated with bacterial vaginosis and, to a lesser extent, with PID. Genital mycoplasmas may be a source of systemic infections, often presenting with sepsis, with Mycoplasma hominis being the most commonly associated pathogen [34,35].
Ureaplasma parvum and Ureaplasma urealyticum are part of the human genital tract microbiota. Distinguishing between these sub-species prevents unnecessary treatment of Ureaplasma parvum, which is generally considered a colonizing pathogen rather than a causative one [36]. However, in a report of ten cases of peritonitis due to Ureaplasma, six were due to the parvum sub-type [11].
Even though Mycoplasma hominis and Ureaplasma parvum agents are not reported as the most aggressive PID etiologies, in our case, it appears that their association, together with Chlamydia trachomatis, led to a rapidly progressive disease.
An early multidisciplinary approach, including consultation with an infectious disease specialist and a clinical pharmacologist, is recommended in cases of peritonitis with an unclear source. Awareness must also be maintained among both gynecologists and general surgeons regarding the potential first presentation of PID as primary peritonitis.
Female patients presenting with PID, regardless of the type of presentation, must receive counseling regarding long-time sequalae which may be a consequence of the long-standing or recurrent inflammatory processes, such as adhesions, scarring, tubal obliteration, traction, and functional impairment. These changes favor tubal ectopic implantation of embryos, lead to infertility, and predispose patients to chronic pelvic pain [37,38]. More recent studies have investigated the potential relationship between PID and subsequent development of endometriosis, with unclear results [39,40], while others have explored the link between PID and genital cancers—ovarian, cervical, and uterine [41,42,43,44,45].
Prophylactic measures, including efforts to increase the level of awareness among adolescents and young adults regarding STI protection, PID symptoms, and methods to avoid infections or attend physicians for a timely diagnosis and correct management, are mandatory.

4. Conclusions

In conclusion, although rare, primary peritonitis caused by genital tract pathogens in the form of acute PID must be considered in sexually active young women with unexplained peritoneal infection, particularly when conventional cultures are negative and no gastrointestinal or gynecologic source is evident intraoperatively.

Author Contributions

Conceptualization, G.N. and M.A.N.; methodology, M.A.N.; C.M.G., I.G.G., and M.S.; resources, M.S.; data curation, I.G.G. and C.M.G.; writing—original draft preparation, M.A.N.; writing—review and editing, G.N. and I.G.G.; visualization, I.C.R. and D.M.; supervision, I.C.R. and D.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Ethical review and approval were waived for this study due to the nature of a single case report.

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
STISexually transmitted infections
HIVHuman immunodeficiency virus
PIDPelvic inflammatory disease
NAATNucleic acid amplification test

References

  1. Shroff, S. Infectious Vaginitis, Cervicitis, and Pelvic Inflammatory Disease. Med. Clin. N. Am. 2023, 107, 299–315. [Google Scholar] [CrossRef]
  2. De Francesco, M.A.; Stefanelli, P.; Carannante, A.; Corbellini, S.; Giagulli, C.; Lorenzin, G.; Ronconi, M.; Arici, E.; Cadei, M.; Campora, R.; et al. Management of a Case of Peritonitis Due to Neisseria gonorrhoeae Infection Following Pelvic Inflammatory Disease (PID). Antibiotics 2020, 9, 193. [Google Scholar] [CrossRef]
  3. Yusuf, H.; Trent, M. Management of Pelvic Inflammatory Disease in Clinical Practice. Ther. Clin. Risk Manag. 2023, 19, 183–192. [Google Scholar] [CrossRef]
  4. Greydanus, D.E.; Bacopoulou, F. Acute pelvic inflammatory disease: A narrative review. Pediatr. Med. 2019, 2, 183–192. [Google Scholar] [CrossRef]
  5. Greydanus, D.E.; Dodich, C. Pelvic inflammatory disease in the adolescent: A poignant, perplexing, potentially preventable problem for patients and physicians. Curr. Opin. Pediatr. 2015, 27, 92–99. [Google Scholar] [CrossRef] [PubMed]
  6. Darville, T. Pelvic Inflammatory Disease Due to Neisseria gonorrhoeae and Chlamydia trachomatis: Immune Evasion Mechanisms and Pathogenic Disease Pathways. J. Infect. Dis. 2021, 224, S39–S46. [Google Scholar] [CrossRef] [PubMed]
  7. Greydanus, D.E.; Cabral, M.D.; Patel, D.R. Pelvic inflammatory disease in the adolescent and young adult: An update. Disease-A-Month 2022, 68, 101287. [Google Scholar] [CrossRef] [PubMed]
  8. Di Franco, S.; Alfieri, A.; Fiore, M.; Fittipaldi, C.; Pota, V.; Coppolino, F.; Sansone, P.; Pace, M.C.; Passavanti, M.B. A Literature Overview of Secondary Peritonitis Due to Carbapenem-Resistant Enterobacterales (CRE) in Intensive Care Unit (ICU) Patients. Antibiotics 2022, 11, 1347. [Google Scholar] [CrossRef]
  9. Sara Fernandes, A.F.-G.; Girão, J.; Miranda, C.; Coutinho, J. Primary pneumococcal peritonitis in a healthy woman: Case report and a literature review of the last 10 years. Port. J. Surg. 2020, 49, 82–87. [Google Scholar]
  10. Liu, T.; Lai, S.Y.; Zhou, W.; Liu, Y.L.; Chen, S.S.; Jiang, Y.M. Analysis of Ureaplasma urealyticum, Chlamydia trachomatis, Mycoplasma genitalium and Neisseria gonorrhoeae infections among obstetrics and gynecological outpatients in southwest China: A retrospective study. BMC Infect. Dis. 2022, 22, 283. [Google Scholar] [CrossRef]
  11. Petri, F.; Gemayel, F.; El Zein, S.; Tande, A.J.; Thoendel, M.J.; Berbari, E.F. Tiny but Nasty: A case report and a review of the literature on Ureaplasma parvum peritonitis. IDCases 2024, 37, e02015. [Google Scholar] [CrossRef]
  12. Kirkoyun Uysal, H.; Koksal, M.O.; Sarsar, K.; Ilktac, M.; Isik, Z.; Akgun Karapinar, D.B.; Demirci, M.; Ongen, B.; Buyukoren, A.; Kadioglu, A.; et al. Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium among Patients with Urogenital Symptoms in Istanbul. Healthcare 2023, 11, 930. [Google Scholar] [CrossRef] [PubMed]
  13. Yu, J.; Zhou, Y.; Luo, H.; Su, X.; Gan, T.; Wang, J.; Ye, Z.; Deng, Z.; He, J. Mycoplasma genitalium infection in the female reproductive system: Diseases and treatment. Front. Microbiol. 2023, 14, 1098276. [Google Scholar] [CrossRef] [PubMed]
  14. Jensen, J.S.; Cusini, M.; Gomberg, M.; Moi, H.; Wilson, J.; Unemo, M. 2021 European guideline on the management of Mycoplasma genitalium infections. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 641–650. [Google Scholar] [CrossRef] [PubMed]
  15. Chen, L.; Nie, Z.; Zhao, Y.; Bao, B. Peritonitis-associated with peritoneal dialysis following Ureaplasma parvum infection: A case report and literature review. Indian J. Med. Microbiol. 2023, 45, 100410. [Google Scholar] [CrossRef]
  16. Goller, J.L.; De Livera, A.M.; Fairley, C.K.; Guy, R.J.; Bradshaw, C.S.; Chen, M.Y.; Hocking, J.S. Characteristics of pelvic inflammatory disease where no sexually transmitted infection is identified: A cross-sectional analysis of routinely collected sexual health clinic data. Sex. Transm. Infect. 2017, 93, 68–70. [Google Scholar] [CrossRef]
  17. Reekie, J.; Donovan, B.; Guy, R.; Hocking, J.S.; Kaldor, J.M.; Mak, D.B.; Pearson, S.; Preen, D.; Stewart, L.; Ward, J.; et al. Risk of Pelvic Inflammatory Disease in Relation to Chlamydia and Gonorrhea Testing, Repeat Testing, and Positivity: A Population-Based Cohort Study. Clin. Infect. Dis. 2018, 66, 437–443. [Google Scholar] [CrossRef]
  18. Chappell, C.A.; Wiesenfeld, H.C. Pathogenesis, diagnosis, and management of severe pelvic inflammatory disease and tuboovarian abscess. Clin. Obstet. Gynecol. 2012, 55, 893–903. [Google Scholar] [CrossRef]
  19. Kreisel, K.M.; Llata, E.; Haderxhanaj, L.; Pearson, W.S.; Tao, G.; Wiesenfeld, H.C.; Torrone, E.A. The Burden of and Trends in Pelvic Inflammatory Disease in the United States, 2006–2016. J. Infect. Dis. 2021, 224, S103–S112. [Google Scholar] [CrossRef]
  20. Workowski, K.A.; Bachmann, L.H.; Chan, P.A.; Johnston, C.M.; Muzny, C.A.; Park, I.; Reno, H.; Zenilman, J.M.; Bolan, G.A. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm. Rep. 2021, 70, 1–187. [Google Scholar] [CrossRef]
  21. Özdemir, Y.E.; Ensaroğlu, E.; Akkaya, S.; Çizmeci, Z.; Kart-Yaşar, K. Clinical Outcomes and Microbiological Profiles of Patients with Culture-Confirmed Peritonitis. Infect. Dis. Clin. Microbiol. 2025, 7, 88–96. [Google Scholar] [CrossRef]
  22. Aw, A.E.Y.; Lee, J.W.K.; Tay, K.V. Primary Peritonitis Secondary to Streptococcus pyogenes in a Young Female Adult-A Case Report and Literature Review. Infect. Dis. Rep. 2021, 13, 26–32. [Google Scholar] [CrossRef] [PubMed]
  23. Chen, L.Y.; Harnod, T.; Chang, Y.H.; Chen, H.; Ding, D.C. The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study. J. Clin. Med. 2021, 10, 4145. [Google Scholar] [CrossRef] [PubMed]
  24. Drexel, S.; Tseng, D. Primary Peritonitis: An Index Case of Mycoplasma hominis Infection in a Healthy Female. Case Rep. Surg. 2018, 2018, 4587801. [Google Scholar] [CrossRef] [PubMed]
  25. Rai, B.; Antoun, I.; Rai, S.; Sood, B. Primary Peritonitis Secondary to Klebsiella Pneumoniae in a Healthy Individual—A Case Report and Literature Review on a Rare Event. Internet J. Surg. 2014, 31, 78980242. [Google Scholar]
  26. Blevrakis, E.; Anyfantakis, D.; Blevrakis, E.; Vlachakis, I. Primary bacterial peritonitis in a previously healthy adolescent female: A case report. Int. J. Surg. Case Rep. 2016, 28, 111–113. [Google Scholar] [CrossRef]
  27. Ugrinovic, S.; Firth, H.; Kavanagh, D.; Gouliouris, T.; Gurugama, P.; Baxendale, H.; Lachmann, P.J.; Kumararatne, D.; Gkrania-Klotsas, E. Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency. Clin. Exp. Immunol. 2020, 202, 379–383. [Google Scholar] [CrossRef]
  28. Sumiyama, F.; Sakaguchi, T.; Yamamichi, K.; Sekimoto, M. Peritonitis caused by group A streptococcus: A case report and literature review. Int. J. Surg. Case Rep. 2022, 92, 106839. [Google Scholar] [CrossRef]
  29. Matsumoto, Y.; Shimizu, A.; Ogawa, K.; Kuroki, S.; Ikuta, K.; Senda, E.; Kagawa, H.; Shio, S. Primary Peritonitis Due to Group A Streptococcus Successfully Treated with Intraperitoneal Drainage. Intern. Med. 2024, 63, 1229–1235. [Google Scholar] [CrossRef]
  30. Barrés-Fernández, A.; Piolatti-Luna, A.; Bretón-Martínez, J.R.; Crehuá-Gaudiza, E.; Quiñones-Torrelo, C.; Moscardó-Navarro, A.; Fuertes-Latasa, C.; Martínez-Costa, C. Case Report: Primary Peritonitis as the Onset of Pediatric Ménétrier’s Disease. Front. Pediatr. 2020, 8, 589853. [Google Scholar] [CrossRef]
  31. Antonik, M.; Ovens, K.J.; Labib, P.L.; Briggs, C.D. Chlamydia (lymphogranuloma venereum) peritonitis in a male patient. BMJ Case Rep. 2021, 14, e240526. [Google Scholar] [CrossRef] [PubMed]
  32. Gizzatullin, T. Primary Bacterial Peritonitis in a Young Man: A Rare Manifestation of Invasive Group A Streptococcal Infection. Cureus 2024, 16, e73549. [Google Scholar] [CrossRef] [PubMed]
  33. Chienwichai, K.; Sangaew, S.; Chuachanpipat, L.; Chang, A. Comparison of clinical outcomes between culture-negative and positive peritonitis in patients undergoing maintenance peritoneal dialysis: A prospective cohort study. BMC Nephrol. 2023, 24, 340. [Google Scholar] [CrossRef] [PubMed]
  34. Moridi, K.; Hemmaty, M.; Azimian, A.; Fallah, M.H.; Khaneghahi Abyaneh, H.; Ghazvini, K. Epidemiology of genital infections caused by Mycoplasma hominis, M. genitalium and Ureaplasma urealyticum in Iran; a systematic review and meta-analysis study (2000–2019). BMC Public Health 2020, 20, 1020. [Google Scholar] [CrossRef]
  35. Leli, C.; Mencacci, A.; Latino, M.A.; Clerici, P.; Rassu, M.; Perito, S.; Castronari, R.; Pistoni, E.; Luciano, E.; De Maria, D.; et al. Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: An Italian observational multicentre study. J. Microbiol. Immunol. Infect. 2018, 51, 220–225. [Google Scholar] [CrossRef]
  36. Lobão, T.N.; Campos, G.B.; Selis, N.N.; Amorim, A.T.; Souza, S.G.; Mafra, S.S.; Pereira, L.S.; Dos Santos, D.B.; Figueiredo, T.B.; Marques, L.M.; et al. Ureaplasma urealyticum and U. parvum in sexually active women attending public health clinics in Brazil. Epidemiol. Infect. 2017, 145, 2341–2351. [Google Scholar] [CrossRef]
  37. Frock-Welnak, D.N.; Tam, J. Identification and Treatment of Acute Pelvic Inflammatory Disease and Associated Sequelae. Obstet. Gynecol. Clin. N. Am. 2022, 49, 551–579. [Google Scholar] [CrossRef]
  38. Hunt, S.; Vollenhoven, B. Pelvic inflammatory disease and infertility. Aust. J. Gen. Pract. 2023, 52, 215–218. [Google Scholar] [CrossRef]
  39. Ye, H.; Tian, Y.; Yu, X.; Li, L.; Hou, M. Association Between Pelvic Inflammatory Disease and Risk of Endometriosis: A Systematic Review and Meta-Analysis. J. Womens Health 2024, 33, 73–79. [Google Scholar] [CrossRef]
  40. Clarizia, R.; Capezzuoli, T.; Ceccarello, M.; Zorzi, C.; Stepniewska, A.; Roviglione, G.; Mautone, D.; Petraglia, F.; Ceccaroni, M. Inflammation calls for more: Severe pelvic inflammatory disease with or without endometriosis. Outcomes on 311 laparoscopically treated women. J. Gynecol. Obstet. Hum. Reprod. 2021, 50, 101811. [Google Scholar] [CrossRef]
  41. Syed Khaja, A.S.; Saleem, M.; Zafar, M.; Moursi, S.; Mohammed, G.E.Y.; Shahid, S.M.A.; Hammam, S.; Moussa, S.; Alharbi, M.S.; Alshammari, A.N. Association between pelvic inflammatory disease and risk of ovarian, uterine, cervical, and vaginal cancers—A meta-analysis. Arch. Gynecol. Obstet. 2024, 310, 2577–2585. [Google Scholar] [CrossRef]
  42. Chang, C.Y.-Y.; Lin, K.Y.-H.; Huang, C.-C.; Lin, W.-C. Association of pelvic inflammatory disease (PID) with ovarian cancer: A nationwide population-based retrospective cohort study from Taiwan. BMC Women’s Health 2021, 21, 274. [Google Scholar] [CrossRef]
  43. Hosseininasab-nodoushan, S.-A.; Ghazvini, K.; Jamialahmadi, T.; Keikha, M.; Sahebkar, A. Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis. Semin. Cancer Biol. 2022, 86, 923–928. [Google Scholar] [CrossRef]
  44. Jonsson, S.; Jonsson, H.; Lundin, E.; Häggström, C.; Idahl, A. Pelvic inflammatory disease and risk of epithelial ovarian cancer: A national population-based case-control study in Sweden. Am. J. Obstet. Gynecol. 2024, 230, 75.e1–75.e15. [Google Scholar] [CrossRef]
  45. Huang, J.-Y.; Ma, K.S.-K.; Wang, L.-T.; Chiang, C.-H.; Yang, S.-F.; Wang, C.-H.; Wang, P.-H. The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease. Cancers 2023, 15, 833. [Google Scholar] [CrossRef]
Figure 1. Initial aspect of pelvic cavity at laparoscopic entry with a significant amount of purulent collection.
Figure 1. Initial aspect of pelvic cavity at laparoscopic entry with a significant amount of purulent collection.
Diagnostics 16 00134 g001
Table 1. Patient STI infection panel result.
Table 1. Patient STI infection panel result.
Sexually Transmitted Diseases Panel—Nucleic Acid Amplification Testing (NAAT) from Cervico-Vaginal Swab Collection
Pathogenic AgentPatient ResultsReference Value
Chlamydia trachomatispositivenegative
Mycoplasma hominispositivenegative
Ureaplasma parvumpositivenegative
Neisseria gonorrhoeaenegativenegative
Mycoplasma genitaliumnegativenegative
Ureaplasma urealyticumnegativenegative
Trichomonas vaginalisnegativenegative
Table 2. Blood test results of patients during the admission timeframe (red—increased values; blue—decreased values).
Table 2. Blood test results of patients during the admission timeframe (red—increased values; blue—decreased values).
Blood TestValue
Day 1
Value
Day 2
Value
Day 4
Value
Day 6
Reference RangesUnits
White blood cell count21.4524.839.979.474–10(103/μL)
Red blood cell count4.413.833.613.924–5(104/μL)
Hemoglobin13.111.610.611.412.0–15.5(g/dL)
Hematocrit39.834.732.834.837–47(%)
Platelet count357318351414150–400(104/μL)
Prothrombin index77 8280–151(%)
Activated partial thromboplastin time36.3 42.623.5–36.5(s)
Sodium134 142140136–146(mmol/L)
Potassium3.7 3.493.953.5–5.1(mmol/L)
Blood urea nitrogen24 302017–43(mg/dL)
Creatinine0.78 1.160.820.51–0.95(mg/dL)
Total bilirubin1.31 0.20.310.3–1.2(mg/dL)
Albumin 3.63.4–5.4(g/dL)
AST22 2696<35(IU/L)
ALT10 2098<35(IU/L)
Lactate dehydrogenase 281<247(IU/L)
Amylase 25–110(IU/L)
C-reactive protein16.6718.854.632.18<0.5(mg/dL)
Procalcitonin 0.5560.1870.0620.1(ng/mL)
Ferritin147 10810–120(ng/mL)
Fibrinogen681 200–400(mg/dL)
AST: aspartate aminotransferase; ALT: alanine aminotransferase; NAAT: nucleic acid amplification test.
Table 3. Microorganisms isolated from PID patients.
Table 3. Microorganisms isolated from PID patients.
Microorganisms Involved in PID
Most Frequently IdentifiedOther Microorganisms
Chlamydia trachomatis
Neisseria gonorrhoeae
Mycoplasma genitalium
Mycoplasma hominis
Ureaplasma urealyticum
Ureaplasma parvum
Neisseria meningitides
Gardnerella vaginalis
Group B Streptococcus (S. agalactiae)
Bacteroides species (fragilis, bivius, disiens)
Streptococcus faecalis
Haemophilus influenzae
Coliforms (Enterobacteriaceae)
Enterococcus
Cytomegalovirus
Peptostreptococcus
Other anaerobes
Table 4. Primary peritonitis cases previously reported in the literature in both female and male patients.
Table 4. Primary peritonitis cases previously reported in the literature in both female and male patients.
StudyPatient Characteristics (Gender, Age, and Special Mentions)Peritoneal Fluid
Microbiologic Samples
Treatment
Rai, 2014 [25]Female
43 years
Klebsiella pneumoniae
-
empiric ampicillin, gentamicin, and metronidazole
-
oral cefalexin
Blevrakis, 2016 [26]Female
14 years
Mild upper respiratory infection two weeks ago
Streptococcus pneumoniae (serotype 3)
-
empiric ceftazidime and metronidazole
-
ceftriaxone
Drexel, 2018 [24]Female
42 years
Uterine fibroids
Gram stain—negative
16S ribosome testing—Mycoplasma hominis RNA
-
empiric antibiotics for PID (ceftriaxone, azithromycin, and metronidazole IV)
-
doxycycline p.o.
Ugrinovic, 2020 [27]Female
16 years
Presumptive diagnosis—appendicitis
Streptococcus pneumoniae
-
piperacillin–tazobactam
Sumiyama, 2022 [28]Female
56 years
Abnormal vaginal discharge for two weeks
Group A Streptococcus
-
empiric meropenem for six days
-
levofloxacin orally
Petri, 2024 [11]Female
36 years
History of metastatic sigmoid colon adenocarcinoma
Ureaplasma parvum
-
empiric piperacillin/tazobactam, later with caspofungin and vancomycin add-on
-
doxycycline orally
Matsumoto, 2024 [29]Female
42 years
Cesarean section three months prior
Group A Streptococcus
-
empiric piperacillin/tazobactam
-
penicillin G and clindamycin
Barrés-Fernández, 2020 [30]Male
11 years
Initial diagnosis—peritonitis and pleural effusion
Final—Ménétrier’s Disease
Negative
-
empiric—cefotaxime
-
empiric—vancomycin was added
Antonik, 2021 [31]Male
49 years
Chlamydia trachomatis
Syphilis serology positive
-
oral doxycycline
-
single-dose of benzathine penicillin
Gizzatullin, 2024 [32]Male
35 years
Group A Streptococcus
-
empiric cefuroxime and metronidazole
-
amoxicillin–clavulanate and clindamycin
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nemeti, G.; Neag, M.A.; Goidescu, I.G.; Surcel, M.; Goidescu, C.M.; Rotar, I.C.; Muresan, D. Polymicrobial PID Presenting as Primary Peritonitis in a Young Immunocompetent Patient—Case Report and Disease Perspectives. Diagnostics 2026, 16, 134. https://doi.org/10.3390/diagnostics16010134

AMA Style

Nemeti G, Neag MA, Goidescu IG, Surcel M, Goidescu CM, Rotar IC, Muresan D. Polymicrobial PID Presenting as Primary Peritonitis in a Young Immunocompetent Patient—Case Report and Disease Perspectives. Diagnostics. 2026; 16(1):134. https://doi.org/10.3390/diagnostics16010134

Chicago/Turabian Style

Nemeti, Georgiana, Maria Adriana Neag, Iulian Gabriel Goidescu, Mihai Surcel, Cerasela Mihaela Goidescu, Ioana Cristina Rotar, and Daniel Muresan. 2026. "Polymicrobial PID Presenting as Primary Peritonitis in a Young Immunocompetent Patient—Case Report and Disease Perspectives" Diagnostics 16, no. 1: 134. https://doi.org/10.3390/diagnostics16010134

APA Style

Nemeti, G., Neag, M. A., Goidescu, I. G., Surcel, M., Goidescu, C. M., Rotar, I. C., & Muresan, D. (2026). Polymicrobial PID Presenting as Primary Peritonitis in a Young Immunocompetent Patient—Case Report and Disease Perspectives. Diagnostics, 16(1), 134. https://doi.org/10.3390/diagnostics16010134

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop